Webcast 
1.50 CME

Optimizing Outcomes with LAI PrEP and ART

Webcast 
1.50 CME

Drilling Down on Interleukin-33

Webcast 
1.50 CME

New Avenues in Hypertension

Webcast 
1.50 AMA PRA

Epithelial Cytokines in the Spotlight

Webcast 
1.50 CME

Eosinophilic Esophagitis in the Spotlight

Webcast 
1.00 CME

CA Part 2: CAR T-Cell Therapy in NHL Subtypes

Webcast 
1.00 CME

FL Part 2 - CAR T-cell Therapy in NHL Subtypes

Webcast Series 
1.25 AMA PRA

Calling the Shots

Webcast 
1.50 CME

Optimizing Outcomes with LAI PrEP and ART

Advanced Clinical Decision Making in HIV Care

Faculty: Meredith E. Clement, MD, MHSc; Monica Gandhi, MD, MPH; Paul E. Sax, MD
Release: 10/21/2026
Expiration: 11/22/2026
Webcast 
1.50 CME

Drilling Down on Interleukin-33

New Treatment Avenues for COPD and Acute Respiratory Infections

Webcast 
1.50 CME

New Avenues in Hypertension

Evolving Management of Uncontrolled and Resistant Disease

Faculty: John M. Flack, MD, MPH; Karol Watson, MD, PhD ; Kausik Umanath, MD, MS, FACP, FASN
Release: 10/20/2026
Expiration: 11/21/2026
Webcast 
1.50 AMA PRA

Epithelial Cytokines in the Spotlight

Focusing on Chronic Rhinosinusitis With Nasal Polyps

Faculty: Joseph K. Han, MD, FARS, FAAOA; Rohit K. Katial, MD; Stella Lee, MD
Release: 10/18/2026
Expiration: 11/18/2026
Webcast 
1.50 CME

Eosinophilic Esophagitis in the Spotlight

Epithelial Cytokines from Disease Pathogenesis to Biologic Treatment

Faculty: Maureen Bauer, MD; Evan Dellon, MD, MPH; Girish Hiremath, MD, MPH
Release: 10/10/2026
Expiration: 11/10/2026
Webcast 
1.00 CME

CA Part 2: CAR T-Cell Therapy in NHL Subtypes

A Case-Based Workshop

Faculty: Ayad Hamdan, MD
Release: 10/08/2026
Expiration: 11/12/2026
Webcast 
1.00 CME

FL Part 2 - CAR T-cell Therapy in NHL Subtypes

A Case-Based Workshop

Faculty: Frederick Locke, MD
Release: 09/23/2026
Expiration: 10/28/2026
Webcast Series 
1.25 AMA PRA

Calling the Shots

Course 1: Immunotherapy for Older Adults With Metastatic cSCC
Course 2: Anticipating and Managing Immune-Related Adverse Events
Course 3: Defining High Risk and the Role of Adjuvant Immunotherapy
Course 4: Individualizing Immunotherapy for Metastatic cSCC
Course 5: Adjuvant Immunotherapy for Very High-Risk CSCC